TABLE 2.
Fixed-effects model measures for interventions evaluated in the included studies have been represented by the mean difference.
| Outcomes measured | Network meta-analysis results (MD; 95% CI) | SUCRA | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TBZ vs. PBO | DTBZ vs. PBO | VBZ vs. PBO | TBZ vs. DTBZ | TBZ vs. VBZ | DTBZ vs. VBZ | TBZ | DTBZ | VBZ | PBO | ||
| UHDRS TMC | −3.50 (-3.78,-3.22) | −2.50 (-3.71,-1.30) | −3.20 (-4.37,-2.03) | −1.00 (−2.23,0.24) | −0.30 (−1.51,0.90) | 0.70 (−0.98,2.37) | 0.878 | 0.422 | 0.700 | 0.000 | |
| UHDRS Total motor |
−3.30 (-3.91,-2.69) | −4.00 (-1.61,-1.01) | −4.30 (-6.81,-1.78) | 0.70 (−1.85,3.24) | 1.00 (−1.59,3.59) | 0.30 (−3.21,3.82) | 0.506 | 0.712 | 0.781 | 0.000 | |
| ESS | −1.80 (1.55,2.05) | −0.30 (−2.6,2.0) | / | −2.10 (0.77,3.43) | / | / | 0.000 | 0.835 | / | 0.664 | |
| BARS-G | / | −0.20 (−0.48,0.08) | 0.30 (0.06,0.54) | / | / | −0.50 (-0.87,-0.13) | / | 0.958 | 0.005 | 0.537 | |
| BARS-T | / | −0.30 (−0.83,0.23) | 0.30 (−0.14,0.75) | / | / | −0.60 (−1.29,0.10) | / | 0.909 | 0.070 | 0.521 | |
Abbreviations: BARS-G, barnes akathisia scale global score; BARS-T, barnes akathisia scale total score; DTBZ, deutetrabenazine; ESS, epworth sleepiness scale; PBO, placebo; TBZ, tetrabenazine; UHDRS TMC, Unified Huntington’s Disease Rating Scale Total Maximal Chorea; VBZ, valbenazine. Bold values indicate statistically significant mean differences in pairwise comparisons or interventions ranking first in the surface under the cumulative ranking curve.